Email updates

Keep up to date with the latest news and content from International Archives of Medicine and BioMed Central.

Open Access Highly Accessed Case report

Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report

Thomas E Ichim1, Fabio Solano2, Fabian Lara2, Eugenia Paris3, Federico Ugalde2, Jorge Paz Rodriguez2, Boris Minev4, Vladimir Bogin15, Famela Ramos1, Erik J Woods6, Michael P Murphy7, Amit N Patel8, Robert J Harman9 and Neil H Riordan1*

Author Affiliations

1 Medistem Inc, San Diego, USA

2 Medistem Panama, City of Knowledge, Clayton, Panama

3 Hospital CIMA, San Jose, Costa Rica

4 University of California, San Diego, California, USA

5 Cromos Pharma, Longview, Washington, USA

6 General Biotechnology, Indianapolis, Indiana, USA

7 Division of Medicine, Indiana University School of Medicine, Indiana, USA

8 Dept of Cardiothoracic Surgery, University of Utah, Salt Lake City, Utah, USA

9 Vet-Stem Inc, Poway, California, USA

For all author emails, please log on.

International Archives of Medicine 2010, 3:30  doi:10.1186/1755-7682-3-30

Published: 11 November 2010


Cellular therapy for spinal cord injury (SCI) is overviewed focusing on bone marrow mononuclear cells, olfactory ensheathing cells, and mesenchymal stem cells. A case is made for the possibility of combining cell types, as well as for allogeneic use. We report the case of 29 year old male who suffered a crush fracture of the L1 vertebral body, lacking lower sensorimotor function, being a score A on the ASIA scale. Stem cell therapy comprised of intrathecal administration of allogeneic umbilical cord blood ex-vivo expanded CD34 and umbilical cord matrix MSC was performed 5 months, 8 months, and 14 months after injury. Cell administration was well tolerated with no adverse effects observed. Neuropathic pain subsided from intermittent 10/10 to once a week 3/10 VAS. Recovery of muscle, bowel and sexual function was noted, along with a decrease in ASIA score to "D". This case supports further investigation into allogeneic-based stem cell therapies for SCI.